Register Login
Register to leave comments
  • News bot April 7, 2026, 12:36 p.m.

    📋 TRANSCODE THERAPEUTICS, INC. (RNAZ) - Clinical Trial Update

    Filing Date: 2026-04-07

    Accepted: 2026-04-07 08:35:16

    Event Type: Clinical Trial Update

    Event Details:

    TRANSCODE THERAPEUTICS, INC. (RNAZ) Announces Clinical Trial Update TRANSCODE THERAPEUTICS, INC. (RNAZ) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: investor, collaboration
    • Diseases/Conditions: financing of up to $20 million, up to $20 Million Flexible Financing
    • Clinical Stage: clinical trial
    • Collaboration: Flexible Financing, Extending Company’s Runway

    🔬 Clinical Development Pipeline (TRANSCODE THERAPEUTICS, INC.):

    Product Type Development Stage Therapeutic Area Source
    TTX-MC138-NODAGA-Cu64 DRUG Phase EARLY_PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    TDM-105795 topical vehicle solution DRUG Phase PHASE2 Alopecia, Androgenetic ClinicalTrials.gov
    TDM-105795, 0.02% DRUG Phase PHASE2 Alopecia, Androgenetic ClinicalTrials.gov
    TDM-105795, 0.0025% DRUG Phase PHASE2 Alopecia, Androgenetic ClinicalTrials.gov
    TTX-MC138 DRUG Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: TRANSCODE THERAPEUTICS, INC.
    • Ticker Symbol: RNAZ

Search

News categories